COSMO Pharmaceuticals N.V. Logo

COSMO Pharmaceuticals N.V.

Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.

COPN | SW

Overview

Corporate Details

ISIN(s):
NL0011832936
LEI:
724500OX0EBQRYTVV639
Country:
Netherlands
Address:
Sir Rogerson's Quay Riverside II, Dublin 2 Dublin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products for gastroenterology, dermatology, and healthtech. The company's therapeutic focus is on the oral and endoscopic treatment of colon diseases, including bowel diseases and colorectal cancer prevention, utilizing its proprietary MMX® technology. In addition to its own pipeline, Cosmo provides manufacturing services to other pharmaceutical companies. These services cover the production of solid, semi-solid, and liquid oral medicines and include process assessment, technology transfer, stability testing, market release, and regulatory documentation support.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-21 02:00
Regulatory News Service
Cosmo Pharmaceuticals receives regulatory approval by the European Commission f…
English 6.1 KB
2025-10-21 02:00
Regulatory News Service
Cosmo Pharmaceuticals erhält nach positiver Stellungnahme des CHMP die behördli…
German 7.2 KB
2025-10-07 02:00
Regulatory News Service
Cosmo Pharmaceuticals announces regulatory approval of Winlevi® in South Korea
English 5.2 KB
2025-10-07 02:00
Regulatory News Service
Cosmo Pharmaceuticals gibt die behördliche Zulassung von Winlevi® in Südkorea b…
German 6.2 KB
2025-08-27 02:00
Regulatory News Service
Cosmo Receives Positive CHMP Opinion for Winlevi® for Treatment of Acne in Adul…
English 7.4 KB
2025-08-27 02:00
Regulatory News Service
Cosmo erhält positive CHMP-Stellungnahme für Winlevi® zur Behandlung von Akne b…
German 8.8 KB
2025-08-08 02:00
Regulatory News Service
Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of O…
English 4.7 KB
2025-08-08 02:00
M&A Activity
Cosmo und Takeda verlängern ihre strategische Produktionsvereinbarung für die w…
German 5.0 KB
2025-08-06 02:00
Business and Financial Review
Cosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffir…
English 3.3 KB
2025-08-06 02:00
Earnings Release
Cosmo Pharmaceuticals bestätigt, dass keine Auswirkungen durch geplante US-Zöll…
German 4.0 KB
2025-07-23 02:00
Earnings Release
Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance …
English 22.3 KB
2025-07-23 02:00
Earnings Release
Cosmo liefert starke Ergebnisse im ersten Halbjahr 2025, erhöht EBITDA-Guidance…
German 24.4 KB
2025-07-17 02:00
Regulatory News Service
Cosmo announces launch of Winlevi® for Treatment of Acne in Singapore and Malay…
English 9.5 KB
2025-07-17 02:00
Regulatory News Service
Cosmo: Markteinführung von Winlevi® zur Behandlung von Akne in Singapur und Mal…
German 10.7 KB
2025-07-16 02:00
Environmental & Social Information
Cosmo Accelerates Global ESG Leadership with Major Ratings Upgrades, UN Compact…
English 6.4 KB

Automate Your Workflow. Get a real-time feed of all COSMO Pharmaceuticals N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for COSMO Pharmaceuticals N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for COSMO Pharmaceuticals N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
PEPTONIC Medical AB Logo
Develops clinically proven self-care products for women's intimate health.
Sweden PMED
Develops sustained-release peptide medicines for chronic & neurodegenerative disorders.
South Korea 087010
Perseus Proteomics Inc. Logo
Develops antibody drugs for cancer, provides research support, and sells diagnostic reagents.
Japan 4882
PharmAbcine Inc. Logo
Develops antibody therapies for cancer, eye diseases, and vascular-related disorders.
South Korea 208340
Pharma Foods International Co., Ltd. Logo
Researches and sells functional ingredients and direct-to-consumer health & beauty products.
Japan 2929
Pharma Mar S.A. Logo
Develops and commercializes marine-derived oncology treatments for rare cancers.
Spain PHM
Pharmanutra Logo
Researches and markets nutritional supplements & medical devices for all ages.
Italy PHN
PHARMARESEARCH BIO Co., Ltd. Logo
A global biopharma firm creating regenerative medicine, pharmaceuticals, devices, and cosmetics.
South Korea 217950
PharmaResearch Co., Ltd. Logo
Develops regenerative medicine, devices & cosmetics using marine biotechnology.
South Korea 214450
PharmaSGP Holding SE Logo
Develops and markets leading natural OTC drugs for chronic conditions in the European market.
Germany PSG

Talk to a Data Expert

Have a question? We'll get back to you promptly.